Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
No Access to Radiotherapy Cannot Explain Reduced Survival in Black Women Post–Breast Cancer Surgery
In the Literature
August 2011, Vol 2, No 5
Black women who undergo mastectomy or lumpectomy for advanced breast cancer have shorter survival duration than their white, Hispanic, and Asian counterparts, regardless of whether they undergo radiation therapy after the procedure, according to a new study (Martinez SR, et al. Cancer. Epub ahead of print. June 20, 2011).
Read More
Combination Therapy Improves Survival in Men with Intermediate-Risk, Early-Stage Prostate Cancer
In the Literature
August 2011, Vol 2, No 5
A new large clinical trial funded by the National Cancer Institute has demonstrated the best approach to therapy for men with intermediaterisk, early-stage prostate cancer that can prolong survival.
Read More
FDA Warns Oncologists: Thermography No Substitute for Mammography
FDA Approvals, News & Updates
August 2011, Vol 2, No 5
The FDA has issued a warning to healthcare providers against substituting breast thermography formammography in screening for breast cancer.
Read More
New Molecular Test Approved to Detect HER2 in Women with Breast Cancer
FDA Approvals, News & Updates
August 2011, Vol 2, No 5
Read More
Novel Nasal Spray Formulation of Fentanyl Citrate for Cancer Pain
FDA Approvals, News & Updates
August 2011, Vol 2, No 5
Read More
Benchmarks for Measuring the Success of a Medical Home in Oncology
By
Robert Gamble
;
Mary Kruczynski
Cancer Care
,
Personalized Medicine
August 2011, Vol 2, No 5
As we move forward in the scheme of healthcare reform, we are being directed toward an integrated care model, one with high quality and economic efficiency. Recently, a model known as an accountable care organization (ACO) was introduced by the US Department of Health and Human Services in the form of a proposed rule open for public comment.
Read More
Patients with Cancer at Risk for Bankruptcy
By
Caroline Helwick
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—Nearly 2% of patients with cancermay file for personal bankruptcy 5 years after their diagnosis, according to researchers from Fred Hutchinson Cancer Research Center in Seattle who presented their data at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
Upper GI Cancers: Are We Getting Value for the Money?
By
Audrey Andrews
ASCO Annual Meeting
August 2011, Vol 2, No 5
Upper GI Malignancies” was a plenary session at ASCO 2011, with 2 experts discussing whether results of recent clinical trials of targeted agents are clinically meaningful or just statistically positive, and what is the value of the enormous amount of money spent in treating noncolorectal gastrointestinal (GI) cancer.
Read More
Northwestern University Comprehensive Cancer Center
Oncology
August 2011, Vol 2, No 5
Interview with Al B. Benson III, MD, FACP,
Professor of Medicine and Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
Read More
Post-ASCO Survey: Oncologists’ and Payers’ Treatment and Coverage Decisions
By
Caroline Helwick
Reimbursement
August 2011, Vol 2, No 5
An analysis of payer and provider responses to key clinical information presented at the ASCO 2011 annual meeting offers a glimpse of the oncology landscape shared by oncologists and health plans.
Read More
Page 311 of 329
308
309
310
311
312
313
314
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
AUGTYRO (Repotrectinib) for the Treatment of ROS1-Positive Non-Small Cell Lung Cancer
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma